Radium-223 chloride (BAY88-8223)

DRUG2 trials

Sponsors

Bayer

Conditions

Bone MetastasesBreast CancerMetastasesPharmacokineticsProstate Cancer

Phase 1

Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

CompletedNCT00748046

BayerMetastases, Pharmacokinetics, Prostate Cancer

Start: 2008-08-31End: 2009-10-31Updated: 2014-06-25

Phase 2

BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease

CompletedNCT01070485

BayerBone Metastases, Breast Cancer

Start: 2010-01-31End: 2012-01-31Updated: 2014-06-25